Key Takeaways from the Third National Parkinson’s Project Advisory Council Meeting

Nov 18, 2026 Nora Wong

On November 9, 2026, the Advisory Council on Parkinson's Research, Care and Services (ACPRCS), established under the National Parkinson's Project (NPP), held its third public meeting in Washington, D.C. The meeting focused on public-private partnerships, with researchers, federal partners, advocacy groups, industry representatives and people with lived experience discussing how research collaborations can advance diagnostics and treatments for Parkinson’s disease and related disorders (PDRDs), including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA).

Ahead of the meeting, CurePSP submitted public comment calling for actionable recommendations that address the needs of people living with PDRDs. The comment emphasized shared investments when they are transferrable, adapting approaches when disease characteristics affect implementation and targeted investments when a shared approach cannot adequately address an important need. Read CurePSP’s public comment here.

Key Takeaways

  • Congressional champions emphasized measurable goals, continued research and access to care. Representatives Gus Bilirakis (FL) and Paul Tonko (NY) and Senators Shelley Moore Capito (WV) and Chris Murphy (CT) provided opening remarks. CurePSP Council Member Jessica Shurer introduced recorded remarks from former Representative Jennifer Wexton, who described her experience living with PSP. Speaking through an AI-assisted recreation of her voice, Wexton called for research investment, better healthcare professional education, coordinated specialty care and care partner support. She urged the Council to sustain its commitment on behalf of herself and the PDRD community and to intentionally address the distinct, historically overlooked needs of those with “related diseases” like PSP.
  • Earlier diagnosis and better tools must be paired with efforts to make advances accessible. Presentations on adaptive deep brain stimulation and diagnostic biomarkers highlighted progress alongside barriers in clinician training, insurance coverage and clinical adoption of new tests. Recommendations included planning early for the evidence that regulators, insurers and providers need and validating diagnostic tools in diverse populations. An MRI-based diagnostic aid that helps distinguish Parkinson’s disease from PSP and MSA offered an example directly relevant to the CurePSP community. Alzheimer’s research provided a cautionary lesson: Medicare coverage for an imaging test came more than a decade after approval.
  • Shared research resources need sustained support to benefit people across diseases. Recommendations included recruiting larger, more diverse groups, linking biological findings with symptoms, making data easier to compare and combine and sustaining research tools and trained staff over time. Presentations included data from the CurePSP Genetics Program, which uses remote participation and at-home blood collection to expand access to research. Biology and genetics research is less developed for PSP, CBD and MSA than for PD. Gaps in samples, diagnostic confirmation and brain donation and banking will require targeted resources. 
  • Research participation should be easier and more responsive to participants’ needs. Discussions highlighted remote participation, fewer duplicate procedures across studies and returning research results to participants. These approaches could ease the burden on individuals and care partners while reaching people from more diverse backgrounds and locations. Speakers also noted that study designs should accommodate for mobility, communication and care needs that change as diseases progress. The Council also acknowledged the need for more lived experience perspectives on future meeting panels.
  • Public-private partnerships need clear goals and meaningful involvement from the communities they serve. Lessons from the Accelerating Medicines Partnership (AMP) programs, such as AMP ALS, illustrated how patient organizations, people living with the disease and care partners can guide research priorities, study design and measures of success. A key challenge is accounting for differences in biology, symptoms and progression within and across diseases. Incorporating PSP, CBD and MSA into specific partnership activities and investments like AMP PDRD must translate into research infrastructure, resources and activities suited to those conditions. This reinforces CurePSP’s call for defined partnership responsibilities, measurable milestones and public reporting that shows whether partnerships are delivering benefits across the populations they intend to serve.

Public Comment Highlights

The Council heard eleven oral public comments from people living with PDRDs and their loves ones. Their accounts grounded the urgency of the Council’s work in daily life. Speakers asked for immediate help alongside the search for a cure, including timely specialist care, guidance and community connection at the time of diagnosis and better health coverage for medications and rehabilitation. CurePSP volunteer and advocate Charmaine, who traveled to Washington D.C. to provide her oral public comment in-person, implored the Council not to leave people living with corticobasal syndrome (CBS) behind.

Commenters also called for accountability in carrying out the National Plan, increased research funding, attention to environmental exposures, and earlier recognition of disease in people at risk, along with more opportunities for them to take part in research. Their recommendations reinforced the powerful message that progress must deliver both future scientific breakthroughs and improvements that people living with these diseases and their families can experience today.

Next Steps for the PSP, CBD and MSA Community

The next Advisory Council meeting will be held virtually on December 7, 2026, and will focus on timely access to high-quality multidisciplinary care that responds to shifting care needs. Two National Academies public workshops planned for 2027 will provide additional evidence and perspective to inform the Council’s recommendations on research, care, services and supports.

CurePSP will continue working to shape recommendations that connect national priorities to specific actions and measurable progress for all the populations the NPP is intended to serve.

You can stay engaged by:

  • Following CurePSP advocacy updates
  • Sharing your experiences with the NPP as a public comment by emailing nationalPDplan@nih.gov, whether you are living with PSP, CBD or MSA or are a care partner
  • Monitoring future NPP activities, including upcoming Advisory Council meetings, recordings of past meetings, workshops and public engagement opportunities.